Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Stop Retinal Ganglion Cell Dysfunction Study
NCT02390284 · University of Miami · PHASE3 · terminated · last registry update 2025-08-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint.” | – | Registry record, University of Miami |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGFR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-22Phase 3 first posted: YS Life Science Co., Ltd., Bimatoprost ophthalmic solution 0.01% YSBP + bimatoprost ophthalmic solution 0.01% (Lumigan®) (NCT07661329)
- 2026-05-07Results posted on the registry: Laboratorios Sophia S.A de C.V., Dorzolamide-timolol-brimonidine and latanoprost + Dorzolamide-timolol and latanoprost (NCT04702789)
- 2026-05-07Also stopped (terminated): Laboratorios Sophia S.A de C.V., Dorzolamide-timolol-brimonidine and latanoprost + Dorzolamide-timolol and latanoprost (NCT04702789)
- 2026-03-27Phase 3 first posted: Glaukos Corporation, Gen 2 Travoprost Intracameral Implant + Timolol eye drops 0.5% (NCT07495852)
- 2026-02-27Phase 3 first posted: Triple Hair Inc, TH07 + TH07 (NCT07435012)
- 2026-01-26Also stopped (terminated): Baylor Research Institute, Pitocin (NCT02910115)
- 2026-01-21Phase 3 first posted: Qlaris Bio, Inc., QLS-111-FDC + Latanoprost (0.005%) (NCT07354516)
- 2025-10-20Phase 3 first posted: SpyGlass Pharma, Inc., Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5% (NCT07218783)
- 2025-10-20Phase 3 first posted: SpyGlass Pharma, Inc., Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5% (NCT07218796)
- 2025-10-16Results posted on the registry: Brigham and Women's Hospital, 15-methyl prostaglandin F2α + Methylergonovine Maleate (NCT03584854)
- 2025-10-15Also stopped (terminated): Massachusetts Eye and Ear Infirmary, Latanoprost eluting contact lens + Topical Latanoprost (NCT04500574)
- 2025-07-24Phase 3 first posted: Alcon Research, Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution + Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NCT07082816)
- 2025-05-30Results posted on the registry: Nicox Ophthalmics, Inc., NCX 470 0.065% (initial phase of trial) + Latanoprost 0.005% (initial phase of trial) (NCT04445519)
- 2025-05-07Phase 3 first posted: University Hospital Dubrava, Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution + Placebo (NCT06960629)
- 2025-01-29Also stopped (terminated): Sight Sciences, Inc., Latanoprost plus adjunctive glaucoma medication (NCT06407973)
- 2024-10-31Phase 3 first posted: Santen Pharmaceutical Co., Ltd., DE-117B Eye Drops + Latanoprost (NCT06666855)
- 2024-10-15Results posted on the registry: Glaukos Corporation, Travoprost Intracameral Implant exchanged at Month 12 + Travoprost Intracameral Implant exchanged at Month 3 (NCT06582732)
- 2024-10-01Results posted on the registry: Ocular Therapeutix, Inc., OTX-TIC (NCT04360174)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision